Cargando…
JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
The identification of a constitutively active JAK2 mutant, namely JAK2-V617F, was a milestone in the understanding of Philadelphia chromosome-negative myeloproliferative neoplasms. The JAK2-V617F mutation confers cytokine hypersensitivity, constitutive activation of the JAK-STAT pathway, and cytokin...
Autores principales: | Wolf, Alexandra, Eulenfeld, René, Gäbler, Karoline, Rolvering, Catherine, Haan, Serge, Behrmann, Iris, Denecke, Bernd, Haan, Claude, Schaper, Fred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772110/ https://www.ncbi.nlm.nih.gov/pubmed/24069558 http://dx.doi.org/10.4161/jkst.24574 |
Ejemplares similares
-
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F
por: Gäbler, Karoline, et al.
Publicado: (2013) -
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013) -
JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022) -
The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018) -
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)